Modifier genes for hypertrophic cardiomyopathy

Current Opinion in Cardiology

Volumn 17, Issue 3, 2002, Pages 242-252

  Marian, A J ^a  

^a Section of Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; MITOCHONDRIAL DNA; PROTEIN KINASE;

DISEASE SEVERITY; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN DEATH;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; FAMILY HEALTH; GENES; GENETIC CODE; HUMANS; MUTATION; PEDIGREE; PHENOTYPE; PREVALENCE;

EID: 0036100436     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200205000-00006     Document Type: Review

References (88)

1. Hypertrophic cardiomyopathy: From man to mouse
2. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy
3. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death
4. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
5. Hypertrophic cardiomyopathy: Histopathologic features of sudden death in cardiac troponin t disease
6. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy
7. Sudden death in young competitive athletes. Clinical, demographic, and pathologic profiles
8. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990
9. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults
10. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations
11. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy
12. On genetic and phenotypic variability of hypertrophic cardiomyopathy: Nature versus nurture
13. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy
14. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations
15. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy
16. What is Kearns-Sayre syndrome after all?
17. Myotonic dystrophy: Molecular windows on a complex etiology
18. A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation
19. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere
20. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy
21. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene
22. Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy
23. Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy
24. A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy
25. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy
26. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy
27. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy
28. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy
29. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy
30. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy
31. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene
32. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene
33. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis
34. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy
35. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy
36. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy
37. Structural analysis of the titin gene in hypertrophic cardiomyopathy: Identification of a novel disease gene
38. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle
39. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy
40. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome
41. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis
42. Mitochondrial disorders: Clinical and genetic features
43. Canaries in the coal mine: Mitochondrial DNA and vascular injury from reactive oxygen species
44. Cardiac disease in myotonic dystrophy
45. Friedreich's ataxia and frataxin: Molecular genetics, evolution and pathogenesis
46. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia
47. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu-Val mutation and a 403Arg-Gln mutation
48. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations
49. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
50. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy
51. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene
52. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes
53. Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy
54. Homozygous mutation in cardiac troponin T: Implications for hypertrophic cardiomyopathy
55. A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes
56. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy
57. Molecular pathogenesis of cardiomyopathies
58. Pathogenesis of diverse clinical and pathologic phenotypes in hypertrophic cardiomyopathy
59. Heritability of cardiac size: An echocardiographic and electrocardiographic study of monozygotic and dizygotic twins
60. Familial predisposition of left ventricular hypertrophy
61. Genetic determination of cardiac mass in normotensive rats: Results from an F344xWKY cross
62. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension
63. Searching for genetic determinants in the new millennium
64. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
65. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure
66. High-resolution haplotype structure in the human genome
67. Linkage disequilibrium in the human genome
68. On genetics, inflammation, and abdominal aortic aneurysm: Can single nucleotide polymorphisms predict the outcome?
69. Genetic dissection of complex traits
70. Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy
71. Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: Identification of a functional mutation in the promoter and a new coding variant (T21M)
72. Association of a G994 → T (Val279 → Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy
73. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death
74. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy
75. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy
76. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy
77. Role of the renin-angiotensin system in cardiac hypertrophy
78. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts
79. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
80. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
81. The influence of the angiotensin 1 converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation
82. Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy
83. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy
84. Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy
85. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy
86. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy
87. Compensated cardiac hypertrophy: Arrhythmogenicity and the new myocardial phenotype. I. Fibrosis
88. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy